pl
en
Country
pl
Language
en
Janssen.tv Janssen.tv MENU

Treatment of CRPC patients with abiraterone acetate within the National Health Fund's medication program

Speciality: Oncology
Language : Polski
Broadcast type : Live conference
Duration : 00:11:21
Date: May 26, 2014

Only one medication program is available for CRPC patients. However, some issues can be unclear or ambiguous. Prof. Piotr Wysocki explains how to interpret its individual records.

Lecturers

Prof. Piotr Wysocki
Oncology Prof. Piotr Wysocki Poland Specialist in the field of clinical oncology. Head of the Department of Oncology-Jagiellonian University Medical College in Krakow. President of the Polish Society of Clinical Oncology.

Other in: Oncology

PROSTATE CANCER: WHICH TREATMENT FOR WHICH PATIENT?
Oncology, Urology Live conference PROSTATE CANCER: WHICH TREATMENT FOR WHICH PATIENT? Several lecturers
EN
Metastatic Prostate Cancer
Oncology Live conference Metastatic Prostate Cancer Prof. Piotr Wysocki
Prof Heather Payne
Dr Stefan Hinz
EN
1
PL
New treatment perspectives for CLL patients with del17p.
Hematology, Oncology Live conference New treatment perspectives for CLL patients with del17p. Prof. Krzysztof Giannopoulos, MD, Ph.D
PL
Plenary session IV - Regional Aspects of the Management of Advanced Prostate Cancer – Realities and Best Practice Sharing
Oncology, Urology Live conference Plenary session IV - Regional Aspects of the Management of Advanced Prostate Cancer – Realities and Best Practice Sharing Several lecturers
EN
Plenary session III - Advanced prostate cancer management now and in the future: what are the options? Recommended
Oncology Live conference Plenary session III - Advanced prostate cancer management now and in the future: what are the options? Iwona Skoneczna, MD, Ph.D
Prof Robert Jones
Laurenţia Nicoleta Galeş, MD, Ph.D
EN
The growing need of Real World Data based on Imbruvica® case
Hematology, Oncology The growing need of Real World Data based on Imbruvica® case Several lecturers
PL
How to teach an old dog new tricks – treatment of mCRPC
Oncology Live conference How to teach an old dog new tricks – treatment of mCRPC Tomasz Borkowski, MD, Ph.D
Roman Sosnowski, MD, Ph.D
Prof. Piotr Wysocki
PL
The sooner the better? Evolution of disease and choice of therapy in systemic treatment of prostate cancer
Oncology Live conference The sooner the better? Evolution of disease and choice of therapy in systemic treatment of prostate cancer Prof. Piotr Wysocki
Iwona Skoneczna, MD, Ph.D
PL
When CRPC becomes a challenge. Urologist and Oncologist Aproach - Strong Together
Oncology When CRPC becomes a challenge. Urologist and Oncologist Aproach - Strong Together Jakub Dobruch, MD, Ph.D
Iwona Skoneczna, MD, Ph.D
PL
Czy są kontrowersje w leczeniu raka jajnika? - debata ekspertów.
Gynecology, Oncology Czy są kontrowersje w leczeniu raka jajnika? - debata ekspertów. Lt Col. Lubomir Bodnar, MD, Ph.D
Prof. Ewa Nowak-Markwitz, MD, Ph.D
PL
Assessment of disease progression in patients with castration-resistant prostate cancer
Oncology Open broadcast Assessment of disease progression in patients with castration-resistant prostate cancer Elżbieta Senkus-Konefka, MD, Ph.D
PL
Is a patient with oligometastases a candidate for surgical treatment?
Oncology Live conference Is a patient with oligometastases a candidate for surgical treatment? Roman Sosnowski, MD, Ph.D
PL
What is the role of modern hormone therapy in the treatment of advanced cancer and CRPC?
Oncology Live conference What is the role of modern hormone therapy in the treatment of advanced cancer and CRPC? Tomasz Borkowski, MD, Ph.D
PL
Which patients should continue receiving hormone treatment and which ones should start chemotherapy?
Oncology Live conference Which patients should continue receiving hormone treatment and which ones should start chemotherapy? Jakub Żołnierek, MD, Ph.D
PL
Advanced Prostate Cancer: To what stage of surgical treatment it is justified and when to start treatment at the earliest system?
Oncology Advanced Prostate Cancer: To what stage of surgical treatment it is justified and when to start treatment at the earliest system? Prof. Marcin Słojewski
PL
Defining progression in bones. Diagnostic imaging
Oncology Live conference Defining progression in bones. Diagnostic imaging Elżbieta Senkus-Konefka, MD, Ph.D
PL
Introduction – epidemiology and strategy of procedure
Oncology Live conference Introduction – epidemiology and strategy of procedure Prof. Maciej Krzakowski, MD, Ph.D
PL
Pathomorphological diagnostics and identification of castration resistance
Oncology Pathomorphological diagnostics and identification of castration resistance Dr Marcin Ligaj,
PL
Molecular mechanisms of CRPC development
Oncology Live conference Molecular mechanisms of CRPC development Prof. Piotr Wysocki
PL
Systemic treatment of CRPC patients
Oncology Live conference Systemic treatment of CRPC patients Jakub Żołnierek, MD, Ph.D
PL
Advanced prostate cancer. The role of radiotherapy
Oncology Live conference Advanced prostate cancer. The role of radiotherapy Elżbieta Senkus-Konefka, MD, Ph.D
PL
How to effectively implement multidisciplinary treatment in practice
Oncology Live conference How to effectively implement multidisciplinary treatment in practice Tomasz Borkowski, MD, Ph.D
PL
Treating cancer pain
Oncology Live conference Treating cancer pain Aleksandra Ciałkowska-Rysz, MD, Ph.D
PL
The role of a psycho-oncologist in the treatment process
Oncology Live conference The role of a psycho-oncologist in the treatment process Mariola Kosowicz, MD, Ph.D
PL
Abiraterone acetate - a new drug in mCRPC therapy available in the medication program
Oncology Open broadcast Abiraterone acetate - a new drug in mCRPC therapy available in the medication program Prof. Piotr Wysocki
PL